359 related articles for article (PubMed ID: 18695136)
21. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
[TBL] [Abstract][Full Text] [Related]
22. A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration.
Carvas JS; Pereira RM; Caparbo VF; Fuller P; Silveira CA; Lima LA; Bonfa E; Mello SB
Osteoporos Int; 2010 Oct; 21(10):1723-9. PubMed ID: 19997905
[TBL] [Abstract][Full Text] [Related]
23. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid overcomes adriamycin resistance in acute myeloid leukemia cells by promoting apoptosis.
Fan RF; Chen YX; Fang ZG; Guo XY; Lu Y; Liu LL; Xu YC; Liu XF; Lin DJ
Mol Med Rep; 2016 Dec; 14(6):5660-5666. PubMed ID: 27878279
[TBL] [Abstract][Full Text] [Related]
25. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
[TBL] [Abstract][Full Text] [Related]
26. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
27. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Suominen MI; Rissanen JP; Käkönen R; Fagerlund KM; Alhoniemi E; Mumberg D; Ziegelbauer K; Halleen JM; Käkönen SM; Scholz A
J Natl Cancer Inst; 2013 Jun; 105(12):908-16. PubMed ID: 23682134
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
Bühler H; Hoberg C; Fakhrian K; Adamietz IA
In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Winter MC; Wilson C; Syddall SP; Cross SS; Evans A; Ingram CE; Jolley IJ; Hatton MQ; Freeman JV; Mori S; Holen I; Coleman RE
Clin Cancer Res; 2013 May; 19(10):2755-65. PubMed ID: 23515409
[TBL] [Abstract][Full Text] [Related]
32. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Neville-Webbe HL; Coleman RE; Holen I
Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
[TBL] [Abstract][Full Text] [Related]
33. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
34. Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.
Alfaro Y; Delgado G; Cárabez A; Anguiano B; Aceves C
Mol Cancer; 2013 May; 12():45. PubMed ID: 23705792
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
[TBL] [Abstract][Full Text] [Related]
36. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
37. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.
Allen MR; Kubek DJ; Burr DB
J Bone Miner Res; 2010 Jan; 25(1):98-105. PubMed ID: 19580463
[TBL] [Abstract][Full Text] [Related]
38. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
39. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
[TBL] [Abstract][Full Text] [Related]
40. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
